Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aurora Cannabis ( (TSE:ACB) ) has shared an announcement.
Aurora Cannabis reported its fiscal 2026 second quarter results, showcasing a 15% year-over-year increase in global medical cannabis net revenue to a record $70.5 million and a 22% rise in international medical cannabis revenue to $42.7 million. The company achieved a 52% growth in adjusted EBITDA, reaching $15.4 million, and maintained a strong balance sheet with $141.9 million in cash and a debt-free cannabis business. Despite a decrease in consumer cannabis revenue, Aurora’s strategic focus on high-margin medical cannabis markets and operational efficiencies contributed to improved gross margins and profitability, positioning the company for continued growth.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$7.00 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Spark’s Take on TSE:ACB Stock
According to Spark, TipRanks’ AI Analyst, TSE:ACB is a Neutral.
Aurora Cannabis’s overall score is driven by its strong earnings call performance, highlighting significant revenue growth and a solid cash position. However, ongoing profitability challenges, negative valuation metrics, and bearish technical indicators weigh down the score.
To see Spark’s full report on TSE:ACB stock, click here.
More about Aurora Cannabis
Aurora Cannabis Inc. is a leading global medical cannabis company based in Canada. The company focuses on the production and distribution of medical cannabis products and holds significant market positions in Canada and key international markets.
Average Trading Volume: 801,861
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$362.4M
For an in-depth examination of ACB stock, go to TipRanks’ Overview page.